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Survival analySiS For GaStric cancer DetecteD By enDoScoPic 
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Objectives: The effectiveness of endoscopic screening for gastric cancer has been 
continually evaluated; however, only a few studies have reported its effectiveness. 
Notably morality reduction from cancer screening has not yet been rigorously evalu-
ated in survival analyses, but an important requirement for cancer screening is 
improving survival. We performed survival analysis for gastric cancer detected by 
endoscopic screening and compared the results with those of survival analysis for 
gastric cancer detected by radiographic screening and outpatients. MethOds: The 
subjects of our study were selected from gastric cancer cases registered in 4 cities 
in the Tottori Cancer Registry from 2001 to 2006. The target age group was defined 
as the age in which gastric cancer was diagnosed from 40 to 79 years. Follow-up 
was continued from the date of diagnosis to the time death from gastric cancer or 
up to December 31, 2011. The survival of 3 groups at 5 and 10 years were compared 
using the Kaplan-Meier method with the log-rank test. Results: There were 347 
subjects selected for endoscopic screening, 166 for radiographic screening, and 980 
as outpatients. The 5-year survival rates were follows: 91.2 ± 1.5% (95% CI: 87.6-93.8) 
for endoscopic screening, 84.3 ± 2.9% (77.7-89.1) for radiographic screening, and 66.0 
± 1.6% (62.8-68.9) for outpatients. The 10-year survival rates were follows: 88.5 ± 2.0% 
(83.9-91.9) for endoscopic screening, 80.1 ± 3.6% (71.9-86.2) for radiographic screen-
ing, and 64.6 ± 1.6% (61.3-67.6) for outpatients. The survival rates were significantly 
different in the 3 groups (P < 0.001). cOnclusiOns: The survival rate was higher 
for endoscopic screening than those for radiographic screening and outpatients. 
Since a high survival rate is mainly affected by lead–time bias, the effectiveness of 
endoscopic screening should be further evaluated in term of mortality reduction 
by conducting large-scale and reliable studies.
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ScreeninG For tyPe 2 DiaBeteS: a MetHoDoloGical review anD coSt 
analySiS
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Objectives: Screening for type 2 diabetes (DM) has peaked as a controversial issue 
given the publication of the recent Canadian guidelines and since the clinical trial 
evidence for the effectiveness of DM screening is lacking. MethOds: A two-step 
evidence-based analysis was performed: 1) narrative review of international guide-
lines 2) systematic review of primary studies. MEDLINE, EMBASE, CINAHL, Wiley 
Cochrane, and Centre for Reviews and Dissemination (2008-2012) were used to iden-
tify primary studies comparing the effectiveness of DM screening to usual care. 
Randomized controlled trials and observational studies meeting inclusion criteria 
were meta-analyzed and the quality of evidence was evaluated using GRADE. A 
cost analysis was developed using Ontario claims data and estimating the down-
stream health care costs in Canadian dollars of screening in Ontario. Results: Eight 
guidelines and six studies from 2,780 citations were identified. The recommenda-
tions for universal screening or screening for low to moderate risk individuals were 
heterogeneous, not shown for high or very high risk individuals. The guidelines 
consistently recommended screening for the latter. Screening was associated with 
a lower likelihood of retinopathy (RR: 0.54, 95% CI: 0.32-0.92) and lower absolute % 
HbA1c (MD: -0.32, 95% CI: -0.53, -0.11). Screening was not linked to increased anxi-
ety or false reassurance. One large RCT showed no beneficial effect of screening on 
long-term mortality outcomes. Two observational studies meta-analyzed showed 
no beneficial effect of screening for neuropathy and nephropathy. The quality of 
evidence was moderate to very low. Estimated cost savings is $150.4 million dollars 
using established parameters, with a range of cost savings as low as $16.7 up to 
$280.4 million dollars in sensitivity analysis. cOnclusiOns: Despite its widespread 
acceptance, the evidence for the long-term effectiveness of DM screening is lacking. 
Further clinical and cost analysis in Canada is needed for short-term outcomes to 
help clarify the issue.
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Objectives: To perform a systematic review to evaluate the quality of anticoagu-
lation control in outpatient pharmacist-managed anticoagulation services (PMAS) 
compared to routine medical care (RMC). MethOds: We searched MEDLINE, 
SCOPUS, EMBASE, IPA, CINAHL, Cochrane CENTRAL, with language restriction to 
English. Two authors independently reviewed each study and extracted data for all 
outcomes using a standardized form, with any disagreement resolved by a third 
author. The primary outcome was the quality of warfarin-related anticoagulation 
management using time in therapeutic range (TTR) as an indicator. Warfarin-related 
bleeding, thrombotic events and resource utilization were assessed as secondary 
outcomes. Results: Of 155 articles identified, 23 articles met the criteria for final 
review. Of these, three studies were RCTs and twenty were observational studies. 
Most studies were conducted between year 2000 to 2013 (N= 18, 78%), and study 
follow-up ranged from six to twelve months (N= 13, 57%). Among studies that 
reported patients’ age, the average age ranged from 46 to 80.5 years, and was simi-
lar between PMAS and RMC groups. The majority of patients were treated for atrial 
fibrillation and venous thrombosis. Quality of anticoagulation control was better in 
the PMAS group compared to RMC, as indicated by higher TTRs in the majority of 
the studies (N= 21, 91%). Clinical outcomes were also favorable in the PMAS group 
as evidenced by lower risk of major bleeding (N= 10 of 14, 71%) or thromboembolic 
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Objectives: Evidence from recent studies on statin treatment intensity for second-
ary prevention supports targeting lower low-density lipoprotein (LDL) levels through 
higher intensity statin treatment. This study aims to assess whether achievement 
of the lower LDL threshold is associated with a reduction in cardiovascular out-
comes. MethOds: Retrospective cohort study of adult members of a large health 
fund with pre-existing ischemic heart disease (IHD) treated with statins for at least 
one year during 2006-2010, and with a routine, fasting serum LDL test measures. The 
incidence of the composite Major Adverse Cardiac Events (MACE) was compared 
between three patient groups according to their achieved LDL: (> 70·1-100mg/dl 
(Moderate) vs. > 100·1-130mg/dl (High), and > 70·1-100mg/dl (Moderate) vs. ≤ 70mg/
dl (Low)). Results: Of 52,177 patients treated with statins, 11,647 had an achieved 
LDL (post-statin treatment) of 70mg/dl or below, 29,097 between 70.1-100mg/dl and 
11,433 between 100·1-130mg/dl. Mean follow-up time from achieved LDL to MACE 
was 3·6 years (±1·5), with 10,955 subjects incurring a MACE during follow-up. LDL 
levels 70·1-100mg/dl compared to 100-130mg/dl were associated with a significant 
8% reduction in the incidence of MACE (hazard ratio [HR]= 0·92 [95% CI, 0·88-0·97; 
p= 0·001]), while ≤ 70 mg/dl compared to 70·1-100mg/dl was not (HR= 0·98 [95% CI, 
0·93-1·03; p= 0·374]). Results remained consistent in propensity score–adjusted Cox 
regression, a sensitivity analysis, and in a sub-group analysis, with no demonstrated 
advantage in MACE outcomes for achieved LDL levels ≤ 70mg/dl. cOnclusiOns: 
Among a real-world population of IHD patients adherent to their statin treatment, 
achieving LDL levels below 100mg/dl is associated with significant clinical benefit, 
whereas no additional benefit is gained by achieving LDL levels below 70mg/dl.
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Objectives: To describe the natural history of metastatic prostate cancer in 
patients treated with androgen deprivation therapy (ADT) or orchiectomy in clini-
cal practice. MethOds: Newly diagnosed prostate cancer patients (2004-2010) 
treated with ADT/orchiectomy were identified from the Henry Ford Health System 
tumor registry. Patients were followed through July 31, 2012. Data on disease pro-
gression (rising prostate-specific antigen [PSA] and presence of metastases) were 
collected from medical records and automated data. Time from initial diagnosis 
to metastases was determined by Kaplan-Meier analyses. Results: We iden-
tified 702 patients; 58% ≥ 70 years and 50% African American; 56% of patients 
were initially diagnosed at stage II, 10% at stage III, 22% at stage IV, and 12% had 
missing/unknown stages. Three percent received orchiectomy; 97% received ADT. 
Comprehensive data on testosterone levels were not available. During follow-
up, an additional 8% of patients progressed to metastatic disease (N= 207): 52% 
(107) had evidence of postcastration disease progression (17% rising PSA, 28% 
presence of ≥ 2 new bone metastases, 55% met both criteria). Bone was the most 
common site, occurring in 74% of metastatic patients; 59% of metastatic patients 
developed bone mestastases to spine. Other metastatic sites included distant 
lymph nodes (12%), lung (8%), central nervous system (7%), and other (14%). Mean 
follow-up time was 3.8 years. Kaplan-Meier analysis indicated that by 5 years 
after initial diagnosis, 13% of stage II and 36% of stage III patients developed 
metastases. cOnclusiOns: While the incidence of cancer is routinely collected 
via registries, information on progression or recurrence is sparse. This study is 
one of few to present information on the natural history and disease progression 
of ADT/orchiectomy-treated prostate cancer in a clinical setting. In this study, we 
found 30% of patients were diagnosed with or progressed to metastatic disease. 
This assessment of medical need may inform future resource planning.
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tHe DiaGnoStic anD clinical value oF anti-MutateD citrullinateD 
viMentin antiBoDieS in rHeuMatoiD artHritiS
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Objectives: Objective To assess the diagnostic and clinical value of anti-mutated 
citrullinated vimentin (anti-MCV) antibody for rheumatoid arthritis (RA) via com-
paring with rheumatoid factors (RF) and anti-cyclic citrullinated peptide antibodies 
(anti-CCP). MethOds: Anti-MCV and anti-CCP were determined using enzyme-
linked immunosorbent assay (ELISA), and meanwhile, the RF was detected in 88 
patients with RA and 16 patients with other rheumatic diseases. Receiver operating 
characteristic (ROC) curve was operated to calculate the areas under the curve of RF, 
anti-CCP and anti-MCV, the max Youden indexes were also calculated to determine 
the optimum testing threshold and the corresponding sensitivity and specificity, 
the diagnostic significance of RF, anti-CCP and anti-MCV in RA were analyzed. The 
correlation of erythrocyte sedimentation rate (ESR) and anti-MCV, and C reactive 
protein (CRP) and anti MCV were evaluated by linear-regression analysis. Results: 
The areas under the curve of RF, anti-CCP and anti-MCV were 0.775, 0.847 and 
0.873, respectively. The max Youden indexes of RF, anti-CCP and anti-MCV were 
0.534, 0636 and 0.71, respectively, and the corresponding sensitivity and specificity 
were 78.4% and 75%, 63.6% and 100%, and 77.3% and 93.7%, respectively. A correla-
tion between ESR and anti-MCV antibody, and CRP and anti-MCV antibody levels 
was observed. cOnclusiOns: The sensitivity of anti-MCV is higher compared 
to anti-CCP and is comparable to RF, and its specificity is higher than that of RF. 
Consequently, anti-MCV can be served as a diagnostic index for RA and its expres-
sion is associated with disease activity of RA.
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medication reconciliation, and medication access. This study has a pre-post design 
with control sites to provide scientific evidence of the clinical and economic impact 
of the interventions. The data collected includes measures of health outcomes, 
medication-related problems, and pharmacist interventions. Results: 3,001 
unique patients were seen by the pharmacy teams during the initial 13 months. A 
majority of these patients suffer from uncontrolled diabetes, hypertension or both. 
For patients with baseline A1C> 9%, 30% achieved A1C < 8% in the intervention group 
versus 13% in the control group after 180 days. For patients with initial BP > 140/90, 
87% of patients in the intervention group achieved BP < 140/90 within 45 days. 19,696 
medication-related problems were documented for 1,993 patients. Problems were 
categorized into four groups including appropriateness/effectiveness(43%), medica-
tion safety(18%), medication nonadherence/misuse(27%), and miscellaneous(9%). 
2,150 potential adverse drug events (pADEs) were identified and resolved for patients 
seen by the clinical pharmacy teams. The most common pADEs were excessive dos-
ing, adverse drug reactions, and polypharmacy. cOnclusiOns: The integration of 
clinical pharmacy teams into the patient-centered medical home improves health 
outcomes and medication safety.
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ePiDeMioloGy oF PSycHiatric HoSPitalizationS PuBlic HealtH SySteM 
in Brazil Between 2010 anD 2012
Figueiredo ACDD 
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Objectives: This study aims to analyze the profile of psychiatric hospitalizations 
within the public health service in Brazil between 2010 and 2012, analyzing the main 
causes of hospitalization, according to the International Classification of Diseases 
(WHO CID.10), the profile of patient and place of residence in Brazil. MethOds: Is 
a descriptive study on the profile of psychiatric hospitalizations within the public 
system of Brazil present in the database of the Hospital Information System (HIS) of 
the Ministry of Health from January 2010 to December 2012. Results: Data analysis 
showed that there was no significant change in the number of cases between 2010 
and 2012; the total number has remained at an average of 280.150 admissions per 
year. Remained the same profile of hospitalization: the majority of were for males 
(65%), 40% white, 26% brown and 6% black, and 28% of hospitalized patients do not 
report skin color. The most admissions occurred between the ages of 30 and 49 years 
(50%).Regarding the causes of hospitalization, classified according to ICD-10 (F00-
F99), the pattern found was 35% of the causes of hospitalization for schizophrenia, 
20% are disorders related to alcohol use, 18% are related disorders psychotropic and 
18% are mood disorders. Other causes, such as dementia, and others appear less 
than 5% of cases each. Regarding the profile of admissions by place of residence, it 
was observed that the more developed regions of the country had the highest per-
centage of hospitalizations, Southeast (42%) and South (28%). cOnclusiOns: This 
study show that use of secondary data in surveys, from information system health, 
plus the low cost generated, an important source of epidemiological information, 
especially in countries with universal coverage of public health services such as 
Brazil , in which the majority of the population depends on the public health system.
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PneuMococcal vaccine tarGetinG StrateGy For tHe olDer aDultS: 
cuStoMizeD riSk ProFilinG
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Objectives: Current pneumococcal vaccine campaigns take a broad, primarily age-
based approach to immunization targeting, overlooking many clinical and admin-
istrative considerations necessary in disease prevention and resource planning for 
specific patient populations. We aim to demonstrate the utility of a population-
specific predictive model for hospital-treated pneumonia to direct effective vaccine 
targeting. MethOds: Data was extracted for 1,053,435 members of an Israeli HMO, 
age 50 and older, during the study period 2008-2010. We developed and validated 
a logistic regression model to predict hospital-treated pneumonia using training 
and test samples, including a set of standard and population-specific risk factors. 
The model’s predictive value was tested for prospectively identifying cases of pneu-
monia and invasive pneumococcal disease (IPD), and was compared to the existing 
international paradigm for patient immunization targeting. Results: In a multi-
variate regression, age, co-morbidity burden and previous pneumonia events were 
most strongly positively associated with hospital-treated pneumonia. The model 
predicting hospital-treated pneumonia yielded a c-statistic of 0.80. Utilizing the 
predictive model, the top 17% highest-risk within the study validation population 
were targeted to detect 54% of those members who were subsequently treated for 
hospitalized pneumonia in the follow up period. The high-risk population identi-
fied through this model included 46% of the follow-up year’s IPD cases, and 27% of 
community-treated pneumonia cases. These outcomes were compared with inter-
national guidelines for risk for pneumococcal diseases that accurately identified 
only 35% of hospitalized pneumonia, 41% of IPD cases and 21% of community-
treated pneumonia. cOnclusiOns: We demonstrate that a customized model for 
vaccine targeting performs better than international guidelines, and therefore, risk 
modeling may allow for more precise vaccine targeting and resource allocation than 
current national and international guidelines. Health care managers and policy-
makers may consider the strategic potential of utilizing clinical and administra-
tive databases for creating population-specific risk prediction models to inform 
vaccination campaigns.
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unDerStanDinG tHe cHoice oF FaMily PlanninG MetHoDS aMonG 
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events (N= 9 of 12, 75 %). This may contribute to improved health care utilization, as 
measured by the lower rates of hospitalization or emergency department visits (N= 7, 
78%). PMAS also resulted in cost-savings in seven of the studies. cOnclusiOns: 
Pharmacist-lead outpatient anticoagulation services attained better quality of anti-
coagulation control, lower bleeding and thromboembolic events, and lower health 
care utilization.
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tHe iMPact oF HoMe MeDication review in PatientS witH tyPe 2 
DiaBeteS MellituS livinG in rural areaS oF kuantan, MalaySia
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Objectives: To investigate whether Home Medication Review (HMR) conducted 
by a pharmacist can improve the clinical indices, quality of life and medication 
adherence in patients with Type 2 Diabetes Mellitus (T2DM). MethOds: Six month 
prospective, randomized, controlled study. Adult T2DM patients taking medications 
for diabetes for at least two years, with HbA1c> 8%, were recruited into the study 
and randomized to intervention or control. The intervention group received three 
home visits by a pharmacist (at baseline, 3 months and at 6 months), and one group 
counselling session with a dietician in addition to the standard medical care. Control 
group patients only received standard medical care. Primary outcome measures 
were HbA1c and fasting blood sugar (FBS). Secondary outcome measures include 
lipid profile (triglycerides, LDL- and HDL-cholesterol); blood pressure (BP); medi-
cation adherence (assessed using modified Morisky adherence scale); and qual-
ity of life (QoL) assessed using the Short form health survey (SF-36v2). Outcomes 
were evaluated at baseline, 3 months and at 6 months. Results: 73 patients were 
recruited and randomized to the intervention group (38) or the control group (35), 
with no significant difference identified in baseline parameters. Data was analysed 
in SPSSv19(IBM) using ANOVA and paired t-test. There were significant improve-
ments from baseline to 6 months in the intervention group in; HbA1c (mean dif-
ference (MD) = 1.57, 95% CI[0.88, 2.26], p< 0.001); FBS (MD= 2.76, 95% CI[0.59,4.94], 
p= 0.009); systolicBP (MD= 6.56, 95% CI[0.75,12.36], p= 0.022); diastolicBP (MD= 4.44, 
95% CI[1.11,7.78], p= 0.006); triglycerides (MD= 0.59, 95% CI[0.24,0.93], p< 0.001) and 
medication adherence (MD= -2.19, 95% CI[-2.73,-1.65], p< 0.001). The control group 
showed no significant changes in outcome measures. QoL improved in the interven-
tion group but declined in controls. cOnclusiOns: In this study, HMR conducted by 
a pharmacist provided significant improvement in health and QoL of patients with 
Type 2 Diabetes Mellitus. HMR may be beneficial for patients with chronic diseases 
and for the health care system.
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incraSeD-DoSe HePatitiS B viruS vaccine iMProve tHe iMMune 
reSPonSe in Hiv-inFecteD PatientS: a Meta-analySiS
Zhao X, Lin P, Wu WK
St John’s University, Jamaca, NY, USA
Objectives: Hepatitis B co-infection may lead to increased mortality of HIV 
patients. All HIV-infected patients are recommended to receive hepatitis B virus 
(HBV) vaccination to prevent the co-infection. However, HIV-infected patients often 
fail to produce protective antibodies to HBV vaccine. This study is sought to assess 
the efficacy of increased-dose HBV vaccine in HIV-infected patients. MethOds: A 
systematic literature review and meta-analysis of clinical trials were conducted. 
The search was carried out on PubMed, EMBASE and the Cochran Database of 
Systematic Reviews, from beginning of databases to December 2013. Keywords 
used in the electronic searches included “hepatitis b”, “HBV”, “vaccine”, “vaccina-
tion”, “immunization”, “HIV”, and “ADIS”. We only included studies those published 
in full-text papers. Inclusion criteria are as follows: English language and rand-
omized control trials those compare the response rates of increased-dose HBV 
vaccine (increase dose or administration times of standard dose) and standard-
dose vaccine (20μ g 3 times at month 0, 1, and 6) in HIV-infected patients. Random 
effect model with heterogeneity analyses were used. The result was reported by 
risk ratio. Statistical analyses were performed using the software program Review 
Manager 5.2. Results: Of 1204 references yielded by electronic searches, five 
trials, which represent a total of 424 patients, were included in the final analysis. 
The heterogeneity was moderate (I2= 32%) according to the I42 test. Pooling of 
study results showed a significant increase in response rate among increased-
dose patients versus control patients; the pooled risk ratio (RR) was 1.17 (95% CI: 
1.06-1.30). The number of intent-to-treat is 9. Only one study presented severe 
adverse reaction reports related to the vaccination, and no increased risk was 
observed. cOnclusiOns: Increasing the dosage of vaccine may improve the 
immune responses significantly in HIV-infected patients.
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inteGration oF clinical PHarMacy ServiceS
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Objectives: Medications must be prescribed and administered properly to be effec-
tive for the treatment of chronic conditions. Medication errors and poor adherence 
lead to increased costs and poor outcomes. Evidence shows that clinical outcomes 
improve when pharmacists are integrated into the care team. The objectives of this 
study were to improve health care quality, medication safety, and reduce health 
care costs for high-risk patients through the integration of clinical pharmacy ser-
vices into patient-centered medical homes. MethOds: Clinical pharmacy teams 
consisting of a pharmacist, resident, and pharmacy technician were integrated into 
five safety net clinics starting in September 2012. Five additional sites were added 
in October 2013. These teams target high-risk patients with poor chronic disease 
control. The services provided include medication and disease state management, 
